DAA-话题@MedSci - 梅斯（MedSci）

#DAA#

53篇内容 | 2507人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1361858, encodeId=b7081361858c8, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=J Hepatol：注射毒品人群中丙型肝炎再感染率随着高效直接抗病毒药物(DAA)使用的扩大而同期上升, objectType=article, longId=218647, objectId=89f421864ed3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89f421864ed3, replyNumber=0, likeNumber=82, createdTime=2021-10-17, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89f421864ed3, moduleTitle=J Hepatol：注射毒品人群中丙型肝炎再感染率随着高效直接抗病毒药物(DAA)使用的扩大而同期上升, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=89f421864ed3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361857, encodeId=c1e7136185e7d, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=CGH：37项临床试验的数据分析表明，使用DAA治疗HCV感染与VZV再激活风险增加之间无关联, objectType=article, longId=217087, objectId=67e521e08795, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67e521e08795, replyNumber=0, likeNumber=83, createdTime=2021-09-16, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67e521e08795, moduleTitle=CGH：37项临床试验的数据分析表明，使用DAA治疗HCV感染与VZV再激活风险增加之间无关联, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=67e521e08795)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361856, encodeId=afc01361856c4, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=Lancet：食品和药物管理局修正案法2007（FDAAA2007）执行情况研究, objectType=article, longId=186550, objectId=92ad186550f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92ad186550f6, replyNumber=0, likeNumber=88, createdTime=2020-01-21, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92ad186550f6, moduleTitle=Lancet：食品和药物管理局修正案法2007（FDAAA2007）执行情况研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=92ad186550f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361855, encodeId=505f136185542, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=Gastroenterology：DAAs与HCV患者肝癌死亡风险, objectType=article, longId=177065, objectId=79271e70654c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79271e70654c, replyNumber=0, likeNumber=95, createdTime=2019-08-08, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79271e70654c, moduleTitle=Gastroenterology：DAAs与HCV患者肝癌死亡风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=79271e70654c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361854, encodeId=8ba913618543b, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=DAA治愈慢性丙型肝炎PEG-IFN联合利巴韦林抗病毒过程中并发重度自身免疫性溶血性贫血1例, objectType=article, longId=161446, objectId=d491161446de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d491161446de, replyNumber=0, likeNumber=77, createdTime=2019-03-02, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d491161446de, moduleTitle=DAA治愈慢性丙型肝炎PEG-IFN联合利巴韦林抗病毒过程中并发重度自身免疫性溶血性贫血1例, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d491161446de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361853, encodeId=732013618538e, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=Hepatology：DAA治疗获得非晚期肝病患者获得SVR后，患者的死亡可得到改善, objectType=article, longId=149809, objectId=71c814980961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71c814980961, replyNumber=0, likeNumber=115, createdTime=2018-09-29, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71c814980961, moduleTitle=Hepatology：DAA治疗获得非晚期肝病患者获得SVR后，患者的死亡可得到改善, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=71c814980961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361852, encodeId=1a88136185211, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=Hepatology：血管生成素2是CHC患者接受DAA治疗后，HCC复发或新发的重要预测因素, objectType=article, longId=149526, objectId=cefb1495267d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cefb1495267d, replyNumber=0, likeNumber=101, createdTime=2018-09-26, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cefb1495267d, moduleTitle=Hepatology：血管生成素2是CHC患者接受DAA治疗后，HCC复发或新发的重要预测因素, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cefb1495267d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361851, encodeId=a9ca136185137, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=J Hepatol：DAA治疗对肝移植的影响：对适应症和结果演变的影响, objectType=article, longId=149472, objectId=1bf71494e28c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bf71494e28c, replyNumber=0, likeNumber=88, createdTime=2018-09-25, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bf71494e28c, moduleTitle=J Hepatol：DAA治疗对肝移植的影响：对适应症和结果演变的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1bf71494e28c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361850, encodeId=ab30136185081, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=Hepatology：DAA没有增加HCC局部治疗患者的HCC复发风险，且能够降低因肿瘤进展或死亡而导致退出等待肝移植名单的风险, objectType=article, longId=147979, objectId=e62714e97924, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e62714e97924, replyNumber=0, likeNumber=109, createdTime=2018-09-02, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e62714e97924, moduleTitle=Hepatology：DAA没有增加HCC局部治疗患者的HCC复发风险，且能够降低因肿瘤进展或死亡而导致退出等待肝移植名单的风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e62714e97924)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361849, encodeId=7c2113618491b, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=Hepatology：DAA治疗时期，有精神健康或物质使用障碍的患者是否有机会接受丙型肝炎病毒治疗?, objectType=article, longId=145516, objectId=943a14551626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=943a14551626, replyNumber=0, likeNumber=104, createdTime=2018-08-01, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=943a14551626, moduleTitle=Hepatology：DAA治疗时期，有精神健康或物质使用障碍的患者是否有机会接受丙型肝炎病毒治疗?, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=943a14551626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361848, encodeId=ab3d136184890, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=Liver Int：：DAA联合治疗肝移植后的丙肝复发是非常有效和耐受的, objectType=article, longId=145290, objectId=b1b614529070, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1b614529070, replyNumber=0, likeNumber=98, createdTime=2018-07-28, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1b614529070, moduleTitle=Liver Int：：DAA联合治疗肝移植后的丙肝复发是非常有效和耐受的, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b1b614529070)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361847, encodeId=be0f136184e70, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=J Viral Hepat：DAA治疗HBV和HCV共感染代偿期肝硬化患者时，HBV病毒再激活的风险, objectType=article, longId=145196, objectId=e18514519623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e18514519623, replyNumber=0, likeNumber=92, createdTime=2018-07-27, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e18514519623, moduleTitle=J Viral Hepat：DAA治疗HBV和HCV共感染代偿期肝硬化患者时，HBV病毒再激活的风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e18514519623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361846, encodeId=8ea31361846dc, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=J Hepatol：DAA药物治疗清除HCV病毒后可改善严重肝纤维化患者的颈动脉粥样硬化, objectType=article, longId=145194, objectId=003414519441, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=003414519441, replyNumber=0, likeNumber=101, createdTime=2018-07-27, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=003414519441, moduleTitle=J Hepatol：DAA药物治疗清除HCV病毒后可改善严重肝纤维化患者的颈动脉粥样硬化, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=003414519441)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361845, encodeId=4612136184587, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=J Hepatol：DAA治疗晚期肝纤维化的HCV患者，其新生HCC的发生率, objectType=article, longId=145191, objectId=71ff14519145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71ff14519145, replyNumber=0, likeNumber=0, createdTime=2018-07-27, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71ff14519145, moduleTitle=J Hepatol：DAA治疗晚期肝纤维化的HCV患者，其新生HCC的发生率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=71ff14519145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361844, encodeId=cec51361844a4, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=Liver Int：采用DAA治疗HCV患者，获得SVR后，晚期肝纤维化和肝硬化患者的随访结果, objectType=article, longId=140301, objectId=8e3114030128, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e3114030128, replyNumber=0, likeNumber=76, createdTime=2018-06-09, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e3114030128, moduleTitle=Liver Int：采用DAA治疗HCV患者，获得SVR后，晚期肝纤维化和肝硬化患者的随访结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8e3114030128)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361842, encodeId=e81c13618424e, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=J Viral Hepat：埃及丙型肝炎患者采用DAA治疗后，肝癌复发率增加, objectType=article, longId=140111, objectId=33241401119a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33241401119a, replyNumber=0, likeNumber=76, createdTime=2018-06-07, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33241401119a, moduleTitle=J Viral Hepat：埃及丙型肝炎患者采用DAA治疗后，肝癌复发率增加, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=33241401119a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361843, encodeId=598d13618437c, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=J Viral Hepat：在荷兰，近期开始采用的DAA治疗方案，对HCV基因1b型患者，治疗较好；但对HCV基因3型患者，疗效较差, objectType=article, longId=140112, objectId=29041401126d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29041401126d, replyNumber=0, likeNumber=119, createdTime=2018-06-07, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29041401126d, moduleTitle=J Viral Hepat：在荷兰，近期开始采用的DAA治疗方案，对HCV基因1b型患者，治疗较好；但对HCV基因3型患者，疗效较差, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=29041401126d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361841, encodeId=672d1361841a3, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=AP&T：直接作用抗病毒药物(DAA)在治疗肝细胞癌的丙型肝炎病毒感染肝硬化患者中效果优良, objectType=article, longId=139463, objectId=c11d139463a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c11d139463a3, replyNumber=0, likeNumber=98, createdTime=2018-06-01, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c11d139463a3, moduleTitle=AP&T：直接作用抗病毒药物(DAA)在治疗肝细胞癌的丙型肝炎病毒感染肝硬化患者中效果优良, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c11d139463a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361840, encodeId=c93e1361840ce, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=Eur J Gastroenterol Hepatol：DAA治疗前后，肝硬度和肝脂肪变性的变化, objectType=article, longId=139290, objectId=25d713929092, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25d713929092, replyNumber=0, likeNumber=90, createdTime=2018-05-29, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25d713929092, moduleTitle=Eur J Gastroenterol Hepatol：DAA治疗前后，肝硬度和肝脂肪变性的变化, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=25d713929092)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361839, encodeId=3a8013618399e, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=BMC Infect Dis：DAA治疗对临床实践的影响, objectType=article, longId=138862, objectId=a96f1388621d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a96f1388621d, replyNumber=0, likeNumber=87, createdTime=2018-05-24, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a96f1388621d, moduleTitle=BMC Infect Dis：DAA治疗对临床实践的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a96f1388621d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

DAA

2020-05-29

qingting (审核中...)

前往app查看评论内容

#DAA#

J Hepatol：注射毒品人群中丙型肝炎再感染率随着高效直接抗病毒药物(DAA)使用的扩大而同期上升

2021-10-17

qingting (审核中...)

前往app查看评论内容

#DAA#

CGH：37项临床试验的数据分析表明，使用DAA治疗HCV感染与VZV再激活风险增加之间无关联

2021-09-16

qingting (审核中...)

前往app查看评论内容

#DAA#

Lancet：食品和药物管理局修正案法2007（FDAAA2007）执行情况研究

2020-01-21

qingting (审核中...)

前往app查看评论内容

#DAA#

Gastroenterology：DAAs与HCV患者肝癌死亡风险

2019-08-08

qingting (审核中...)

前往app查看评论内容

#DAA#

DAA治愈慢性丙型肝炎PEG-IFN联合利巴韦林抗病毒过程中并发重度自身免疫性溶血性贫血1例

2019-03-02

qingting (审核中...)

前往app查看评论内容

#DAA#

Hepatology：DAA治疗获得非晚期肝病患者获得SVR后，患者的死亡可得到改善

2018-09-29

qingting (审核中...)

前往app查看评论内容

#DAA#

Hepatology：血管生成素2是CHC患者接受DAA治疗后，HCC复发或新发的重要预测因素

2018-09-26

qingting (审核中...)

前往app查看评论内容

#DAA#

J Hepatol：DAA治疗对肝移植的影响：对适应症和结果演变的影响

2018-09-25

qingting (审核中...)

前往app查看评论内容

#DAA#

Hepatology：DAA没有增加HCC局部治疗患者的HCC复发风险，且能够降低因肿瘤进展或死亡而导致退出等待肝移植名单的风险

2018-09-02

qingting (审核中...)

前往app查看评论内容

#DAA#

Hepatology：DAA治疗时期，有精神健康或物质使用障碍的患者是否有机会接受丙型肝炎病毒治疗?

2018-08-01

qingting (审核中...)

前往app查看评论内容

#DAA#

Liver Int：：DAA联合治疗肝移植后的丙肝复发是非常有效和耐受的

2018-07-28

qingting (审核中...)

前往app查看评论内容

#DAA#

J Viral Hepat：DAA治疗HBV和HCV共感染代偿期肝硬化患者时，HBV病毒再激活的风险

2018-07-27

qingting (审核中...)

前往app查看评论内容

#DAA#

J Hepatol：DAA药物治疗清除HCV病毒后可改善严重肝纤维化患者的颈动脉粥样硬化

2018-07-27

qingting (审核中...)

前往app查看评论内容

#DAA#

J Hepatol：DAA治疗晚期肝纤维化的HCV患者，其新生HCC的发生率

2018-07-27

qingting (审核中...)

前往app查看评论内容

#DAA#

Liver Int：采用DAA治疗HCV患者，获得SVR后，晚期肝纤维化和肝硬化患者的随访结果

2018-06-09

qingting (审核中...)

前往app查看评论内容

#DAA#

J Viral Hepat：埃及丙型肝炎患者采用DAA治疗后，肝癌复发率增加

2018-06-07

qingting (审核中...)

前往app查看评论内容

#DAA#

J Viral Hepat：在荷兰，近期开始采用的DAA治疗方案，对HCV基因1b型患者，治疗较好；但对HCV基因3型患者，疗效较差

2018-06-07

qingting (审核中...)

前往app查看评论内容

#DAA#

AP&T：直接作用抗病毒药物(DAA)在治疗肝细胞癌的丙型肝炎病毒感染肝硬化患者中效果优良

2018-06-01

qingting (审核中...)

前往app查看评论内容

#DAA#

Eur J Gastroenterol Hepatol：DAA治疗前后，肝硬度和肝脂肪变性的变化

2018-05-29

qingting (审核中...)

前往app查看评论内容

#DAA#

BMC Infect Dis：DAA治疗对临床实践的影响

2018-05-24

科室
- - 订阅+
  - 更多科室
工具
服务